• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微动脉瘤在糖尿病性黄斑水肿发病机制和治疗中的作用:描述性综述。

Role of Microaneurysms in the Pathogenesis and Therapy of Diabetic Macular Edema: A Descriptive Review.

机构信息

Department of Ophthalmology, Faculty of Medical Sciences, University of Fukui, Yoshida 910-1193, Japan.

出版信息

Medicina (Kaunas). 2023 Feb 22;59(3):435. doi: 10.3390/medicina59030435.

DOI:10.3390/medicina59030435
PMID:36984436
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10051835/
Abstract

This study aims to elucidate the role of microaneurysms (MAs) in the pathogenesis and treatment of diabetic retinopathy (DR) and diabetic macular edema (DME), the major causes of acquired visual impairment. We synthesized the relevance of findings on the clinical characteristics, pathogenesis, and etiology of MAs in DR and DME and their role in anti-vascular endothelial growth factor (VEGF) therapy. MAs, a characteristic feature in DR and DME, can be detected by fluorescein angiography, optical coherence tomography (OCT) and OCT angiography. These instrumental analyses demonstrated a geographic and functional association between MA and ischemic areas. MA turnover, the production and loss of MA, reflects the activity of DME and DR. Several cytokines are involved in the pathogenesis of MAs, which is characterized by pericyte loss and endothelial cell proliferation in a VEGF-dependent or -independent manner. Ischemia and MAs localized in the deep retinal layers are characteristic of refractory DME cases. Even in the current anti-VEGF era, laser photocoagulation targeting MAs in the focal residual edema is still an effective therapeutic tool, but it is necessary to be creative in accurately identifying the location of MAs and performing highly precise and minimally invasive coagulation. MAs play a distinctive and important role in the pathogenesis of the onset, progression of DR and DME, and response to anti-VEGF treatment. Further research on MA is significant not only for understanding the pathogenesis of DME but also for improving the effectiveness of treatment.

摘要

本研究旨在阐明微动脉瘤(MAs)在糖尿病性视网膜病变(DR)和糖尿病性黄斑水肿(DME)发病机制和治疗中的作用,DR 和 DME 是获得性视力损害的主要原因。我们综合了有关 DR 和 DME 中 MAs 的临床特征、发病机制和病因及其在抗血管内皮生长因子(VEGF)治疗中的作用的研究结果的相关性。MAs 是 DR 和 DME 的特征性表现,可以通过荧光素血管造影、光学相干断层扫描(OCT)和 OCT 血管造影来检测。这些仪器分析显示 MA 与缺血区域之间存在地理和功能相关性。MA 周转,即 MA 的产生和损失,反映了 DME 和 DR 的活性。几种细胞因子参与了 MAs 的发病机制,其特征是周细胞丧失和内皮细胞增殖,这是 VEGF 依赖性或非依赖性的。缺血和位于深层视网膜的 MA 是难治性 DME 病例的特征。即使在当前的抗 VEGF 时代,针对局灶性残留水肿中的 MA 进行激光光凝仍然是一种有效的治疗工具,但有必要创造性地准确识别 MA 的位置,并进行高度精确和微创的凝固。MA 在 DR 和 DME 的发病机制、进展以及对抗 VEGF 治疗的反应中起着独特而重要的作用。对 MA 的进一步研究不仅对了解 DME 的发病机制具有重要意义,而且对提高治疗效果也具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be0f/10051835/bc2a34aeaf2b/medicina-59-00435-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be0f/10051835/ebffb581f277/medicina-59-00435-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be0f/10051835/b44f1758005a/medicina-59-00435-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be0f/10051835/521a3ff323e1/medicina-59-00435-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be0f/10051835/bc2a34aeaf2b/medicina-59-00435-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be0f/10051835/ebffb581f277/medicina-59-00435-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be0f/10051835/b44f1758005a/medicina-59-00435-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be0f/10051835/521a3ff323e1/medicina-59-00435-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be0f/10051835/bc2a34aeaf2b/medicina-59-00435-g004.jpg

相似文献

1
Role of Microaneurysms in the Pathogenesis and Therapy of Diabetic Macular Edema: A Descriptive Review.微动脉瘤在糖尿病性黄斑水肿发病机制和治疗中的作用:描述性综述。
Medicina (Kaunas). 2023 Feb 22;59(3):435. doi: 10.3390/medicina59030435.
2
Decrease in the number of microaneurysms in diabetic macular edema after anti-vascular endothelial growth factor therapy: implications for indocyanine green angiography-guided detection of refractory microaneurysms.抗血管内皮生长因子治疗后糖尿病性黄斑水肿中微动脉瘤数量减少:对吲哚菁绿血管造影引导下检测难治性微动脉瘤的影响。
Graefes Arch Clin Exp Ophthalmol. 2020 Apr;258(4):735-741. doi: 10.1007/s00417-020-04608-9. Epub 2020 Jan 21.
3
Effect of microaneurysms on the anti-VEGF treatment for diabetic macular edema: A retrospective cross-sectional study.微动脉瘤对糖尿病黄斑水肿抗 VEGF 治疗的影响:一项回顾性横断面研究。
Medicine (Baltimore). 2023 Nov 3;102(44):e35888. doi: 10.1097/MD.0000000000035888.
4
Turnover of Microaneurysms After Intravitreal Injections of Faricimab for Diabetic Macular Edema.Faricimab 玻璃体腔内注射治疗糖尿病性黄斑水肿后微动脉瘤的转归。
Invest Ophthalmol Vis Sci. 2023 Oct 3;64(13):31. doi: 10.1167/iovs.64.13.31.
5
Regional Variety of Reduction in Retinal Thickness of Diabetic Macular Edema after Anti-VEGF Treatment.抗血管内皮生长因子治疗后糖尿病黄斑水肿视网膜厚度降低的区域性差异。
Medicina (Kaunas). 2022 Jul 14;58(7):933. doi: 10.3390/medicina58070933.
6
Optical Coherence Tomography Angiography of DME and Its Association with Anti-VEGF Treatment Response.糖尿病性黄斑水肿的光学相干断层扫描血管造影及其与抗血管内皮生长因子治疗反应的关系。
Ophthalmology. 2016 Nov;123(11):2368-2375. doi: 10.1016/j.ophtha.2016.07.010. Epub 2016 Sep 6.
7
The Role of Laser Photocoagulation in Treating Diabetic Macular Edema in the Era of Intravitreal Drug Administration: A Descriptive Review.激光光凝在眼内药物治疗时代治疗糖尿病性黄斑水肿的作用:描述性综述。
Medicina (Kaunas). 2023 Jul 17;59(7):1319. doi: 10.3390/medicina59071319.
8
Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation.渗漏性黄斑中心凹周围微动脉瘤对采用抗血管内皮生长因子与短脉冲局灶/格栅激光光凝联合治疗的糖尿病性黄斑水肿消退的影响。
Jpn J Ophthalmol. 2017 Jan;61(1):51-60. doi: 10.1007/s10384-016-0483-8. Epub 2016 Oct 11.
9
Pathological Neurovascular Unit Mapping onto Multimodal Imaging in Diabetic Macular Edema.病理性神经血管单元在糖尿病性黄斑水肿的多模态成像中的定位。
Medicina (Kaunas). 2023 May 7;59(5):896. doi: 10.3390/medicina59050896.
10
Characterization of microaneurysm closure after focal laser photocoagulation in diabetic macular edema.糖尿病性黄斑水肿局灶激光光凝后微动脉瘤闭合的特征。
Am J Ophthalmol. 2013 May;155(5):905-12. doi: 10.1016/j.ajo.2012.12.005. Epub 2013 Feb 6.

引用本文的文献

1
Does the Efficacy, Durability, and Safety of Faricimab for Diabetic Macular Edema in Randomized Trials Translate into Real-World Settings?在随机试验中,法西单抗治疗糖尿病性黄斑水肿的疗效、持久性和安全性能否转化到现实环境中?
Ophthalmol Ther. 2025 Sep 19. doi: 10.1007/s40123-025-01233-9.
2
Understanding nonproliferative diabetic retinopathy progression using noninvasive imaging.使用非侵入性成像技术了解非增殖性糖尿病视网膜病变的进展
Eye (Lond). 2025 Jul 11. doi: 10.1038/s41433-025-03901-3.
3
Microaneurysm Counting as a Biomarker for the Hyperperfusion Stage of Nonproliferative Diabetic Retinopathy.

本文引用的文献

1
Regional Variety of Reduction in Retinal Thickness of Diabetic Macular Edema after Anti-VEGF Treatment.抗血管内皮生长因子治疗后糖尿病黄斑水肿视网膜厚度降低的区域性差异。
Medicina (Kaunas). 2022 Jul 14;58(7):933. doi: 10.3390/medicina58070933.
2
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.在糖尿病性黄斑水肿(YOSEMITE 和 RHINE)患者中,每 16 周进行一次玻璃体腔内 faricimab 延长给药的疗效、持久性和安全性:两项随机、双盲、3 期试验。
Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24.
3
微动脉瘤计数作为非增殖性糖尿病视网膜病变高灌注期的生物标志物
Ophthalmol Ther. 2025 Aug;14(8):1905-1915. doi: 10.1007/s40123-025-01179-y. Epub 2025 Jul 1.
4
Impact of Subthreshold Micropulse Laser on the Vascular Network in Diabetic Macular Edema: An Optical Coherence Tomography Angiography Study.阈下微脉冲激光对糖尿病性黄斑水肿血管网络的影响:一项光学相干断层扫描血管造影研究
Biomedicines. 2025 May 14;13(5):1194. doi: 10.3390/biomedicines13051194.
5
The HAT Inhibitor ISOX-DUAL Diminishes Ischemic Areas in a Mouse Model of Oxygen-Induced Retinopathy.组蛋白乙酰转移酶抑制剂ISOX-DUAL可减少氧诱导性视网膜病变小鼠模型中的缺血区域。
Genes Cells. 2025 Mar;30(2):e13196. doi: 10.1111/gtc.13196.
6
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in diabetic macular edema: 2-year results from the Japan subgroup of the phase 3 YOSEMITE trial.Faricimab 的疗效、持久性和安全性,在糖尿病黄斑水肿中最长每 16 周给药一次:来自 3 期 YOSEMITE 试验日本亚组的 2 年结果。
Jpn J Ophthalmol. 2024 Sep;68(5):511-522. doi: 10.1007/s10384-024-01078-y. Epub 2024 Jul 31.
7
Role of MicroRNA in linking diabetic retinal neurodegeneration and vascular degeneration.微小 RNA 在连接糖尿病性视网膜神经退行性变和血管退行性变中的作用。
Front Endocrinol (Lausanne). 2024 Jul 4;15:1412138. doi: 10.3389/fendo.2024.1412138. eCollection 2024.
8
Patterns of Progression of Nonproliferative Diabetic Retinopathy Using Non-Invasive Imaging.应用无创成像技术观察非增殖性糖尿病视网膜病变的进展模式。
Transl Vis Sci Technol. 2024 May 1;13(5):22. doi: 10.1167/tvst.13.5.22.
9
Correlation between Topographic Vessel Density and Retinal Thickness Changes in Patients with Diabetic Macular Edema Treated with Anti-VEGF Therapy: Is It a Suitable OCTA Biomarker?抗VEGF治疗的糖尿病性黄斑水肿患者的地形图血管密度与视网膜厚度变化之间的相关性:它是一种合适的光学相干断层扫描血管造影生物标志物吗?
J Pers Med. 2023 Dec 16;13(12):1718. doi: 10.3390/jpm13121718.
10
OCT-angiography based artificial intelligence-inferred fluorescein angiography for leakage detection in retina [Invited].基于光学相干断层扫描血管造影的人工智能推断荧光素血管造影用于视网膜渗漏检测[特邀报告]
Biomed Opt Express. 2023 Oct 18;14(11):5851-5860. doi: 10.1364/BOE.506467. eCollection 2023 Nov 1.
Microaneurysm Turnover in Mild Non-Proliferative Diabetic Retinopathy is Associated with Progression and Development of Vision-Threatening Complications: A 5-Year Longitudinal Study.
轻度非增殖性糖尿病视网膜病变中微动脉瘤的周转率与视力威胁性并发症的进展和发生相关:一项5年纵向研究
J Clin Med. 2021 May 15;10(10):2142. doi: 10.3390/jcm10102142.
4
Microaneurysm density in residual oedema after anti-vascular endothelial growth factor therapy for diabetic macular oedema.抗血管内皮生长因子治疗糖尿病性黄斑水肿后残余水肿中的微动脉瘤密度
Acta Ophthalmol. 2021 Sep;99(6):e876-e883. doi: 10.1111/aos.14706. Epub 2020 Dec 16.
5
Subthreshold Micropulse Laser in Diabetic Macular Edema: 1-Year Improvement in OCT/OCT-Angiography Biomarkers.阈下微脉冲激光治疗糖尿病性黄斑水肿:光学相干断层扫描/光学相干断层扫描血管造影生物标志物的1年改善情况
Transl Vis Sci Technol. 2020 Sep 30;9(10):31. doi: 10.1167/tvst.9.10.31. eCollection 2020 Sep.
6
Characteristic distribution of microaneurysms and capillary dropouts in diabetic macular edema.糖尿病性黄斑水肿中微动脉瘤和毛细血管无灌注区的特征分布。
Graefes Arch Clin Exp Ophthalmol. 2020 Aug;258(8):1625-1630. doi: 10.1007/s00417-020-04722-8. Epub 2020 May 4.
7
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHANGES AFTER SUBTHRESHOLD MICROPULSE YELLOW LASER IN DIABETIC MACULAR EDEMA.光学相干断层扫描血管造影术在糖尿病黄斑水肿亚阈值微脉冲黄色激光治疗后的变化。
Retina. 2020 Feb;40(2):312-321. doi: 10.1097/IAE.0000000000002383.
8
Decrease in the number of microaneurysms in diabetic macular edema after anti-vascular endothelial growth factor therapy: implications for indocyanine green angiography-guided detection of refractory microaneurysms.抗血管内皮生长因子治疗后糖尿病性黄斑水肿中微动脉瘤数量减少:对吲哚菁绿血管造影引导下检测难治性微动脉瘤的影响。
Graefes Arch Clin Exp Ophthalmol. 2020 Apr;258(4):735-741. doi: 10.1007/s00417-020-04608-9. Epub 2020 Jan 21.
9
Microaneurysm Imaging Using Multiple En Face OCT Angiography Image Averaging: Morphology and Visualization.多层面 OCT 血管成像平均法检测微动脉瘤:形态与可视化。
Ophthalmol Retina. 2020 Feb;4(2):175-186. doi: 10.1016/j.oret.2019.09.010. Epub 2019 Sep 27.
10
Multiple Effects of Intravitreal Aflibercept on Microvascular Regression in Eyes with Diabetic Macular Edema.玻璃体内注射阿柏西普对糖尿病性黄斑水肿患者眼内微血管消退的多重作用
Ophthalmol Retina. 2019 Dec;3(12):1067-1075. doi: 10.1016/j.oret.2019.06.005. Epub 2019 Jun 15.